The journal of nutrition, health & aging

, Volume 16, Issue 4, pp 336–338

Is there a rationale for including only patients already being treated with acetylcholinesterase inhibitors in a prodromal AD trial?

  • M. Grundman
  • E. Yang
  • A. Dibernardo
Is There a Rationale for Including Only Patients Already Being Treated with Cetylcholinesterase

DOI: 10.1007/s12603-012-0020-5

Cite this article as:
Grundman, M., Yang, E. & Dibernardo, A. J Nutr Health Aging (2012) 16: 336. doi:10.1007/s12603-012-0020-5

Abstract

Prodromal AD clinical trial methodology is advancing rapidly. It is now possible to more accurately identify MCI patients with underlying AD pathology at an earlier stage of the disease through the use of amyloid imaging and CSF biomarkers. Measurement of decline in these early stage clinical trials using continuous clinical and cognitive outcome measures is conceptually more appealing and adds greater efficiency compared to the classical outcome of “conversion” to dementia used in prior MCI clinical trials. Nevertheless, the fact that many prodromal AD patients who are likely to be recruited to these early stage studies are not taking acetylcholinesterase inhibitors at the time of enrollment, but are poised to start taking them over a multi-year period of follow-up, is a potential confound that needs to be addressed.

Key words

Clinical trial design MCI prodromal AD symptomatic treatment acetylcholinesterase inhibitors 

Copyright information

© Serdi and Springer Verlag France 2012

Authors and Affiliations

  • M. Grundman
    • 1
  • E. Yang
    • 2
  • A. Dibernardo
    • 3
  1. 1.Global R&D Partners, LLCSan DiegoUSA
  2. 2.Johnson & Johnson Pharmaceutical Research & DevelopmentSpring HouseUSA
  3. 3.Johnson & Johnson Pharmaceutical Research & DevelopmentTitusvilleUSA

Personalised recommendations